A review of the use of next generation sequencing methodologies to identify biomarkers of resistance to CDK4/6 inhibitors in ER+/HER2- breast cancer-Reference-Cited by-同舟云学术

A review of the use of next generation sequencing methodologies to identify biomarkers of resistance to CDK4/6 inhibitors in ER+/HER2- breast cancer

Published:2021-01 Issue: Volume:157 Page:103191
ISSN:1040-8428
Container-title:Critical Reviews in Oncology/Hematology
language:en
Short-container-title:Critical Reviews in Oncology/Hematology

Author:

Servetto Alberto,Napolitano Fabiana,De Angelis Carmine,De Placido Pietro,Giuliano Mario,Arpino Grazia,De Placido Sabino,Bianco Roberto,Formisano Luigi^ORCID

Funder

Associazione Italiana per la Ricerca sul Cancro

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference105 articles.

1. Epigenetic reprogramming at estrogen-receptor binding sites alters 3D chromatin landscape in endocrine-resistant breast cancer;Achinger-Kawecka;Nat. Commun.,2020

2. Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors;Adalsteinsson;Nat. Commun.,2017

3. 3-Phosphoinositide-dependent protein kinase-1 (PDK1): structural and functional homology with the Drosophila DSTPK61 kinase;Alessi;Curr. Biol.,1997

4. A systematic screen for CDK4/6 substrates links FOXM1 phosphorylation to senescence suppression in cancer cells;Anders;Cancer Cell,2011

5. Alpelisib for PIK3CA-Mutated, hormone receptor-positive advanced breast cancer;Andre;N. Engl. J. Med.,2019

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. EGFR and HER2 hyper-activation mediates resistance to endocrine therapy and CDK4/6 inhibitors in ER+ breast cancer;Cancer Letters;2024-07

2. Leveraging the fundamentals of heat transfer and fluid mechanics in microscale geometries for automated next-generation sequencing library preparation;Scientific Reports;2024-05-31

3. Next-generation sequencing-based detection in a breast MMPMN patient with EGFR T790M mutation: a rare case report and literature review;Frontiers in Oncology;2023-07-24

4. Pak1 pathway hyper-activation mediates resistance to endocrine therapy and CDK4/6 inhibitors in ER+ breast cancer;npj Breast Cancer;2023-05-31

5. Facing the CDK4/6i resistance dilemma in patients with breast cancer, exploration of the resistance mechanism and possible reverse strategy: A narrative review;Medicine;2022-12-23